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Abstract  Some  patients  with  autoimmune  liver  disease  have  characteristics  of  cholestasis,
as well  as  of  autoimmune  hepatitis.  Despite  the  fact  that  this  is  a  relatively  frequent  clinical
condition seen  in  referral  centers  for  liver  diseases,  there  is  little  evidence  as  regards  the  clinical
management  of  these  syndromes  due  to  their  low  prevalence  and  the  lack  of  standardized
deﬁnitions  and  diagnostic  criteria.  This  is  relevant,  given  that  published  studies  report  that
there is  a  lower  therapeutic  response  and  poorer  outcome  in  patients  with  overlap  syndrome
than in  those  presenting  solely  with  autoimmune  hepatitis.
Whether  overlap  syndromes  are  distinct  entities  or  the  presence  of  2  concurrent  diseases
is still  a  subject  of  debate.  They  should  be  suspected  in  autoimmune  hepatitis  patients  that
present with  signs  of  cholestasis,  as  it  is  known  that  overlap  behavior  tends  to  be  more  aggres-
sive, with  higher  rates  of  cirrhosis  and  the  need  for  liver  transplantation.  Treatment  response
is also  poorer  and  should  be  directed  at  the  predominant  component.  Standardized  deﬁnitions
are necessary  so  that  these  syndromes  can  be  studied  in  controlled  clinical  trials.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE
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Diagnóstico  y  tratamiento  de  los  síndromes  de  sobreposición  de  hepatitis  autoinmune
Resumen  Algunos  pacientes  con  enfermedad  hepática  autoinmune  poseen  características
Hepatitis
autoinmune;
tanto de  colestasis  como  de  hepatitis  autoinmune.  A  pesar  de  que  es  un  escenario  clínico
relativamente  frecuente  en  unidades  de  referencia  para  la  atención  de  enfermedades  hepáti-Cirrosis  biliar
primaria;
Colangitis
esclerosante  primaria
cas, debido  a  su  baja  prevalencia,  la  falta  de  estandarización  en  deﬁniciones  y  en  criterios
diagnósticos,  existe  poca  evidencia  acerca  de  su  manejo  clínico,  el  cual  es  relevante  ya  que,
de acuerdo  a  lo  descrito,  su  respuesta  terapéutica  es  menor  y  su  pronóstico  es  peor  que  los  de
la hepatitis  autoinmune  aislada. Please cite this article as: Aguilar-Nájera O, Velasco-Zamora JA, Torre A. Diagnóstico y tratamiento de los síndromes de sobreposición
e hepatitis autoinmune. Revista de Gastroenterología de México. 2015;80:150--159.
∗ Corresponding author. Vasco de Quiroga 15, Colonia Sección 16, Del. Tlalpan, México, D.F. CP 14000, extensión 2706 2710. Tel.: +54870900.
E-mail address: detoal@yahoo.com (A. Torre).
255-534X/© 2015 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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En  la  actualidad,  aún  existe  controversia  acerca  de  si  los  síndromes  de  sobreposición  son
entidades  diferentes  o  la  presencia  de  2  enfermedades  coexistentes.  Deben  ser  buscados  en  los
pacientes con  hepatitis  autoinmune  que  tienen  datos  de  colestasis  ya  que  sabemos  que  su  com-
portamiento  tiende  a  ser  más  agresivo  con  mayores  tasas  de  cirrosis  y  necesidad  de  trasplante
hepático así  como  pobre  respuesta  al  tratamiento,  el  cual  debe  ser  dirigido  al  fenotipo  prin-
cipal. Hacen  falta  deﬁniciones  estandarizadas  que  permitan  su  estudio  en  ensayos  clínicos
controlados.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Autoimmune  liver  diseases  are  a  group  of  diseases  char-
acterized  by  an  anomalous  immune  response  directed  at
hepatocytes  or  bile  ducts.  Their  importance  lies  in  the  fact
that  they  can  result  in  chronic  liver  damage  with  ﬁbrosis  and
cirrhosis.1 They  are  classiﬁed  in  relation  to  their  clinical,
biochemical,  serologic,  histologic,  and  radiologic  ﬁndings.
Autoimmune  liver  diseases  are  divided  into  2  groups;  the
ﬁrst  is  characterized  by  predominantly  hepatocellular  dam-
age  and  its  prototype  is  autoimmune  hepatitis  (AIH).  The
second  is  characterized  by  cholestasis  and  includes  primary
biliary  cirrhosis  (PBC)  and  primary  sclerosing  cholangitis
(PSC).2--4
These  diseases  have  been  identiﬁed  as  clinical  syndromes
with  their  own  diagnostic  criteria  and  classic  phenotyp-
ical  presentations.  However,  there  is  no  etiologic  agent
or  characteristic  pathogenic  pathway  whose  measurement
would  enable  us  to  make  an  accurate  diagnosis.5 Evidence
indicates  that  AIH,  PBC,  and  PSC  share  pathophysiologic
mechanisms.  Even  though  these  mechanisms  are  not  yet
fully  understood,  it  is  known  that  they  are  based  on  the
interaction  between  genetic  predisposition  and  triggering
environmental  factors  that,  associated  with  immunologic
self-regulation  defects,  cause  immunotolerance  disruption
and  induce  tissue  damage  mediated  by  antibodies  and  T-
cells.6--8 In  AIH,  histologic  damage  is  observed  predominantly
in  the  portal  and  periportal  hepatocytes,  whereas  in  PBC  and
PSC  the  histologic  lesion  affects  the  biliary  epithelial  cells,
each  with  its  distinctive  characteristics.9
Overlap  syndromes  encompass  a  small  group  of  patients
within  the  spectrum  of  the  autoimmune  liver  diseases  that
can  have  the  characteristics  of  cholestasis  (PBC  or  PSC)  in
combination  with  AIH.10 In  overlap  syndromes  the  character-
istics  of  the  coexisting  diseases  may  present  simultaneously
or  consecutively,  resulting  in  the  ongoing  debate  as  to
whether  these  syndromes  should  be  considered  distinct  enti-
ties  or  variants  of  the  primary  diseases.11 Overlap  syndromes
apparently  affect  young  AIH  patients  more  frequently  and
their  symptoms,  which  are  very  nonspeciﬁc,  include  fatigue,
arthralgia,  and  pruritus.12
Due  to  the  heterogeneous  presentation  of  the  overlap
syndromes,  the  absence  of  standardized  deﬁnitions  and
criteria,  and  the  lack  of  controlled  clinical  trials,  their  treat-
ment  is  largely  empirical  and  extrapolated  from  the  primary
diseases.
(
Lypes and diagnoses of overlap syndromes
ach  one  of  the  autoimmune  liver  diseases  has  spe-
iﬁc  classic  characteristics  (table  1).  Nevertheless,  they
re  not  completely  homogeneous,  and  in  relation  to
ach  disease,  patients  can  present  with  a spectrum
f  different  clinical,  biochemical,  serologic,  and  radio-
ogic  characteristics.  Furthermore,  the  variability  in  the
alidation  and  reproducibility  of  the  criteria  and  diag-
ostic  tests  must  be  taken  into  account,  adding  to
he  complexity  of  their  classiﬁcation  and  differential
iagnoses.12
Approximately  18%  of  the  patients  with  autoimmune
epatopathy  present  with  characteristics  that  are  dis-
inctive  of  a  second  autoimmune  hepatic  disease.  The
erm  overlap  syndrome  refers  to  the  coexistence  of
 autoimmune  diseases  in  the  same  patient.10,13 Thus,
IH  can  present  with  3  cholestatic  phenotypes  that  can
e  intermixed  with  its  classic  ‘‘hepatic’’  characteristics8
table  2).
In relation  to  clinical  practice,  the  presence  of  an  over-
ap  syndrome  should  be  suspected  when,  in  the  setting  of
n  autoimmune  hepatopathy,  there  is  a  deviation  in  its  nat-
ral  progression,  the  biochemical  and  serologic  patterns  are
ot  classic,  or  the  therapeutic  response  is  not  the  expected
ne.14
The  nomenclature  of  the  overlap  syndromes  has  trans-
ormed  over  time.  Speciﬁc  terms  used  to  be  employed  to
eﬁne  some  of  them  (e.g.  autoimmune  sclerosing  cholangitis
or  AIH/PSC  overlap  in  children  or  autoimmune  cholangi-
is  for  the  AIH/undetermined  cholestasis  overlap).  However,
n  order  to  avoid  confusion  and  homogenize  their  classi-
cation,  it  is  recommended  to  ﬁrst  name  the  dominant
henotype  and  then  the  secondary  phenotype  (e.g.  AIH/PBC
r  AIH/PSC).
Unlike  autoimmune  liver  diseases  as  isolated  entities,
verlap  syndromes  lack  speciﬁc  diagnostic  criteria.  There-
ore,  proposals  to  that  end  have  been  made  that  will
e  discussed  further  ahead.  It  is  also  recommended  to
eﬁne  each  of  the  primary  autoimmune  hepatopathies  in
ccordance  with  the  criteria  that  has  been  validated  by
he  different  international  groups  and  associations,  such
s  the  International  Autoimmune  Hepatitis  Group  (IAIHG),
he  American  Association  for  the  Study  of  Liver  Diseases
AASLD),  and  the  European  Association  for  the  Study  of  the
iver  (EASL).15
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Table  1  Characteristics  of  the  patients  with  autoimmune  liver  diseases.
Characteristic  AIH  PBC  PSC
Age  at  onset All  ages  (bimodal  peak),  10-
20 years  and  40-50  years
Mean  age  40  years All  ages  (usually  ≈  40  years)
Sex Women  >  men  (4:1)  Women  >  men  (9:1)  Men  7:3  women
Serology
ANA Titers  >  1:40  (70-80%)  Present  in  ≈  30-40%  of  the
cases
Not  speciﬁc  for  PSC.  Present
in  70-80%
ASMA Titers  >  1:40  (70-80%)  Can  be  present  Greater  than  83%
Anti-LKM-1  3-4%  (classiﬁes  AIH  as  type  2)
Anti-SLA/LP  10-30%  Can  be  present  Can  be  present
pANCA Greater  than  92% 26-94%
AMA In  low  titers  in  ≈  5-10% 95%  of  the  cases  (highly
speciﬁc)
If  it  is  present  it  is  coincidental
Immunoglobulins  Elevated  IgG  (>  1.2  X  over  the
ULN)
elevated  IgM  in  the  majority  of
cases
Elevated  IgG  in  61%
Elevated  IgM  in  45%
Radiology
Cholangiography  Usually  normal.  ≈  10%  of  the
cases  can  have  changes  in  the
intrahepatic  ducts
Normal  Multifocal  stricture  (beaded
pattern)  in  the  entire  biliary
tree.  It  can  be  normal  in  PSC
of the  small  ducts
Histology
Interface hepatitis  Characteristic  ﬁnding  Present  in  a  variable  manner  Present  in  a  variable  manner
Portal inﬂammation  Lymphoplasmacytic  inﬁltrate  Lymphocytic  inﬁltrate  Lymphocytic  inﬁltrate
Biliary changes  ≈  10%  of  the  cases  Inﬂammatory  ductal  lesion  Periductal  ﬁbrosis  (‘‘onion
skin’’  lesion)
Granulomas  No  Characteristic  lesion,  present
in only  some  cases
Atypical  (<  10%)
AIH: autoimmune hepatitis; AMA: anti-mitochondrial antibodies; ANA: anti-nuclear antibodies; ASMA: anti-smooth muscle antibodies;
LKM-1: live kidney microsomal antibodies; pANCA: perinuclear anti-neutrophil cytoplasmic antibodies; PBC: primary biliary cirrhosis;
PSC: primary sclerosing cholangitis; SLA/LP: soluble liver antigen/liver pancreas; ULN: upper limit of normal.
Table  2  Diagnostic  characteristics  of  the  overlap  syndromes.
Overlap
syndrome
Laboratory  characteristics  Serologic
characteristics
Histologic  characteristics  Cholangiography
AIH/PBC  Paris  criteria*
Mild  forms
AP  <  2  ULN
Positive  AMA  Interface  hepatitis
Destructive  cholangitis
Normal
AIH/PSC  AST/ALT  >  ULN
-globulins  and  IgG  >  ULN
AP or  GGT  >  ULN
Negative  AMA  Interface  hepatitis
Ductopenia
Portal  edema  or  ﬁbrosis
Fibro-obliterating
cholangitis
Strictures/dilations
(beaded  pattern)
AIH/cholestatic
syndrome
AST/ALT >  ULN
-globulins  and  IgG  >  ULN
AP or  GGT  >  ULN
Negative  AMA  Interface  hepatitis
Destructive  cholangitis
or bile  duct  loss
Normal
AIH: autoimmune hepatitis; ALT: alanine transaminase; AMA: anti-mitochondrial antibodies; ANA: anti-nuclear antibodies; AP: alkaline
phosphatase; ASMA: anti-smooth muscle antibodies; AST: aspartate transaminase; GGT gamma glutamyltransferase; LKM-1: live kidney
microsomal antibodies; pANCA: perinuclear anti-neutrophil cytoplasmic antibodies; PBC: primary biliary cirrhosis; PSC: primary sclerosing
cholangitis; SLA/LP: soluble liver antigen/liver pancreas; ULN: upper limit of normal.
* Paris criteria. Interface hepatitis and ALT > 5 ULN, IgG > 2 ULN or anti-smooth muscle antibodies and 2 out of 3 PBC characteristics
such as AP > 2 ULN or GGT > 5 ULN.
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Autoimmune  hepatitis  overlap/primary  biliary
cirrhosis
Epidemiology/diagnosis
Due  to  its  low  frequency  and  the  lack  of  standardized
criteria,  the  prevalence  of  AIH/PBC  overlap  is  difﬁcult  to
establish.  Nevertheless,  it  is  estimated  in  2-20%  of  the
patients  with  AIH  and  4.3-9.2%  in  those  with  PBC.16,17 It
is  important  to  mention  that  close  to  10%  of  the  patients
with  all  the  characteristics  of  AIH  can  persistently  have
positive  anti-mitochondrial  antibodies  (AMAs),  but  the  lat-
ter  is  not  synonymous  with  PBC.  O’Brien  et  al.  studied
15  patients  with  AIH  and  positive  AMAs  whose  histologic
studies  did  not  present  with  changes  consistent  with  PBC.18
In  another  study  on  130  patients  with  autoimmune  hepati-
tis,  24  (18%)  had  positive  AMAs.  In  that  study,  having  positive
AMAs  was  not  associated  with  histologic  biliary  lesion,  with
ulterior  PBC  development,  with  different  remission  rates,  or
with  treatment  failure  and  therefore  the  presence  of  AMA
was  insufﬁcient  for  diagnosing  AIH/PBC  overlap  or  predicting
cholestatic  phenotypes.19 Likewise,  AMA  positivity  appears
to  be  transitory,  given  that  in  the  same  study  at  patient
follow-up  54%  remained  positive,  16%  became  negative,  and
the  other  30%  did  not  have  positive  AMAs  at  the  onset  of  the
study,  but  became  positive  during  the  follow-up  period.19
AIH/PBC  overlap  diagnosis  continues  to  be  a  challenge
and  there  is  no  criterion  standard.  The  most  widely  used
criteria  for  its  diagnosis  come  from  2  research  groups:  the
so-called  ‘‘Paris  criteria’’  proposed  by  Chazouillères  et  al.
in  199816 and  the  International  Autoimmune  Hepatitis  Group
(IAIHG).10 A  recent  study  showed  that  the  ‘‘Paris  crite-
ria’’  have  a  high  sensitivity  (92%)  and  speciﬁcity  (97%)  for
AIH/PBC  overlap  diagnosis  and  thus  are  currently  the  most
widely  used.20
When  utilizing  the  Paris  criteria  for  establishing  AIH/PBC
overlap  diagnosis,  at  least  2  of  the  3  criteria  per  entity,  with
the  following  deﬁnitions,  are  required:11
For  PBC:
1.  Alkaline  phosphatase  (AP)  ≥  2  times  the  upper  limit
of  normal  or  gamma  glutamyltransferase  ≥  5  times  the
upper  limit  of  normal.2.  AMA  (≥  1:40)
3.  Liver  biopsy  with  a  ﬂorid  bile  duct  lesion  (degeneration
of  the  bile  duct  epithelium  with  focal  ductal  obliteration
and  granuloma  formation)  (ﬁg.  1).
t
m
r
c
Figure  1  a.  An  epithelioid  granuloma  is  observed  in  the  portal  trac
not typical  of  classic  AIH).  b.  Destruction  of  interlobular  bile  ducts.  
interface and  lobular  inﬁltrate  (asterisk).ment  153
For  AIH:
.  Alanine-amino-transferase  (ALT)  ≥  5  times  the  upper
limit  of  normal.
.  IgG  ≥  2  times  the  upper  limit  of  normal  or  positive  anti-
smooth  muscle  antibodies.
.  Liver  biopsy  with  periseptal  or  periportal  lymphocytic
necrosis.
On  the  other  hand,  the  IAIHG  suggests  applying  the  diag-
ostic  score  for  AIH  to  patients  with  PBC  to  identify  the  cases
ith  AIH  characteristics.  Since  1993  the  IAIHG  diagnostic
riteria  have  been  revised  and  in  2008  they  were  simpliﬁed,
stablishing  a  score  ≥  7  points  as  deﬁnitive  AIH  and  ≥  6  as
robable  AIH.  By  not  giving  the  AMAs  or  the  bile  duct  histo-
ogic  lesion  a  negative  score,  the  simpliﬁed  score  appears  to
etter  identify  the  patients  with  overlap  than  its  extensive
ounterpart.21
In  relation  to  the  serologic  proﬁle  of  AIH/PBC  overlap
yndrome,  Muratori  et  al.  compared  240  patients  (120  with
ure  PBC  and  120  with  pure  AIH)  with  15  patients  that  had
IH/PBC  overlap  according  to  the  Paris  criteria  and  found
hat  the  concomitant  presence  of  AMA  and  anti-nuclear  anti-
odies  was  a highly  speciﬁc  pattern  for  AIH/PBC  overlap.22
On  the  other  hand,  despite  the  fact  that  the  etiology
f  autoimmune  liver  diseases  is  not  yet  understood,  it  is
nown  that  various  environmental  factors  act  in  combina-
ion  with  the  genetic  susceptibility  of  the  individual  to  alter
he  immune  response.  With  respect  to  this,  the  presence
f  AIH  has  been  associated  with  the  major  histocompatibil-
ty  complex,  particularly  with  the  HLA-DR3/DR4  and  HLA-B8
oci,23 but  the  data  on  AIH/PBC  overlap  are  limited.  In  2011
 study  on  this  group  of  patients  found  differences  between
he  HLA-DR  alleles;  the  presence  of  HLA-DR7  was  more  fre-
uent  in  patients  with  overlap  than  in  those  with  AIH,  which
ould  help  distinguish  those  patients  with  AIH  that  are  prone
o  present  with  AIH/PBC  overlap  syndrome.24 Another  study
onducted  on  Mexican  patients  found  that  the  patients  with
BC  had  a higher  frequency  of  HLA-DR4  and  DR1  alleles,
hen  compared  with  healthy  controls  and  patients  with
verlap  syndromes.  On  the  other  hand,  the  healthy  controls
ad  a  higher  frequency  of  the  HLA-DR5  allele,  suggesting
hat  the  latter  could  play  a  protective  role  in  the  develop-
ent  of  liver  autoimmunity.25 There  is  little  information  in
egard  to  this  and  therefore  further  studies  are  needed  to
onﬁrm  these  ﬁndings.
t,  surrounded  by  lymphoplasmacytic  inﬁltrate  (granulomas  are
c.  Chronic  non-suppurative  destructive  cholangitis  (arrow)  and
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reatment/outcome
t  is  a  well-established  fact  that  for  patients  with  PBC,
rsodeoxycholic  acid  (UDCA)  at  a  dose  of  13-15  mg/Kg/d
lows  the  progression  of  ﬁbrosis  and  the  instauration  of
nd-stage  liver  disease,  mainly  in  those  patients  with
iochemical  improvement.  On  the  other  hand,  immuno-
uppressants  are  the  treatment  cornerstone  in  AIH,  and
ts  aim  is  to  achieve  complete  disease  remission  for
he  purpose  of  preventing  and/or  reverting  liver  ﬁbrosis
rogression.26,27
Unfortunately,  the  lack  of  validated  criteria  and  the
carcity  of  clinical  trials  means  that  AIH/PBC  treatment  has
o  be  empirical,  based  on  data  extrapolated  from  primary
utoimmune  liver  diseases  and  sustained  in  retrospective
rials  and  case  series.5,28 With  said  limitations,  the  EASL  and
AIHG  guidelines  recommend  the  combination  of  immuno-
uppressant  drugs  (corticosteroids/azathioprine)  with  UDCA
t  a  dose  of  13-15  mg/kg/d  as  a  ﬁrst  therapeutic  option.  As
n  alternative  form  in  those  patients  with  mild  AIH  activity,
DCA  can  be  used  as  monotherapy,  adding  immunosuppress-
ve  therapy  at  3  months  if  there  has  been  no  biochemical
esponse.
Information  in  relation  to  outcome  in  patients  with
IH/PBC  overlap  is  variable.  Some  studies  have  documented
 worse  outcome  with  a  greater  progression  to  cirrhosis  and
omplications  due  to  portal  hypertension,  when  compared
ith  PBC  as  a  single  entity. 29--30 In  contrast,  other  reports
escribe  a  better  outcome  with  respect  to  progression  to
brosis,  overall  survival,  and  transplant-free  survival  mainly
hen  the  combination  treatment  is  used  and  there  is  good
iochemical  response.5,31
In  conclusion,  AIH/PBC  diagnosis  continues  to  be  a  chal-
enge,  the  Paris  criteria  are  currently  a  good  diagnostic
ool,  and  while  there  are  no  large-scale,  randomized,
nd  prospective  clinical  trials,  the  combination  treatment
immunosuppressants  and  UDCA)  is  recommended.  Those
atients  that  do  not  ﬁt  the  Paris  criteria  for  overlap  should
eceive  treatment  in  accordance  with  the  predominant  phe-
otype.
utoimmune  hepatitis/primary  sclerosing
holangitis  overlap
eﬁnition
IH/PSC  overlap  is  another  of  the  cholestatic  phenotypes
f  AIH  and  is  characterized  by  having  negative  AMAs  and
holangiographic  alterations  in  NMR  cholangiography  or
ndoscopic  retrograde  cholangiography.8 In  patients  with
IH/PSC  overlap  there  is  an  entity  known  as  autoimmune
clerosing  cholangitis  that  presents  in  children  and  is  deﬁned
he  same  as  AIH/PSC  in  adults,  except  that  compared  with
he  latter,  its  treatment  response  is  better.  In  fact,  approx-
mately  50%  of  the  children  with  AIH  have  cholangiographic
lterations.32
Patients  with  PSC  can  have  altered  aminotransferases,
yperglobulinemia,  and  positive  antibodies,  as  well  as  inter-
ace  hepatitis  in  biopsy  in  up  to  30%  of  patients.10A  syndrome  worth  mentioning  only  due  to  its  rareness
s  PBC/PSC.  Its  frequency  has  been  estimated  at  0.7%  in  a
ohort  of  261  patients  with  autoimmune  liver  disease  that
as  been  followed  for  20  years.15,33
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pidemiology
he  existing  variability  in  frequencies  is  most  likely  a  reﬂec-
ion  of  the  characteristics  of  the  cohorts  and  the  diagnostic
ethod  employed.34
The  approximate  frequency  of  PSC  criteria  in  patients
ith  AIH  ranges  from  6-11%8 and  the  prevalence  of  autoim-
une  hepatitis  in  patients  with  PSC  as  the  dominant
henotype  is  from  2-33%.13 Upon  applying  the  revised  IAIHG
riteria  to  patients  with  PSC,  the  prevalence  of  AIH  criteria
s  from  7-14%.
On  the  other  hand,  the  prevalence  of  cholangiographic
lterations  in  patients  with  AIH  is  variable,  depending  on
he  population  studied,  and  is  2-10%  in  adults  with  classic
IH,  41%  in  adults  with  AIH  and  UC,  and  50%  in  children  with
IH.15
A  study  on  79  patients  with  AIH  found  cholangiographic
lterations  through  NMR  cholangiography  that  were  con-
istent  with  PSC  in  10%  of  the  patients.  The  patients
ith  cholangiographic  alterations  had  a  lower  age  at  the
ime  of  diagnosis  and  higher  bilirubin  and  alkaline  phos-
hatase  ﬁgures  than  the  patients  with  no  cholangiographic
lterations.35
Not  all  the  cholangiographic  alterations  in  NMR  cholan-
iography  indicate  the  presence  of  AIH/PSC  overlap.  This
as  illustrated  in  a  study  that  compared  24  patients  pre-
enting  with  AIH  and  cholangiographic  alterations  through
MR  cholangiography  with  27  controls  presenting  with  non-
utoimmune  liver  cirrhosis.  That  study  found  that  the  only
redictor  of  cholangiographic  alterations  was  the  presence
f  liver  ﬁbrosis,  given  that  the  proportion  of  patients  with
holangiographic  alterations  in  the  intrahepatic  bile  ducts
as  had  greater  similarity  to  patients  with  AIH  and  signiﬁ-
ant  ﬁbrosis  (46%)  than  to  the  controls  with  non-autoimmune
irrhosis  (59%).  These  ﬁndings  suggest  that  in  a large  num-
er  of  patients  with  AIH,  the  cholangiographic  alterations
eem  to  be  more  related  to  the  presence  of  ﬁbrosis  than  to
n  actual  AIH/PSC  diagnosis.36
It  has  consistently  been  stated  that  AIH  and  PBC  are
ore  frequent  in  women  and  that  PSC  is  more  frequent  in
en.  Interestingly,  that  tendency  is  maintained  in  AIH/PSC
verlap,  with  approximately  62%  of  the  cases  presenting  in
en.13
athogenesis
IH  and  PSC  share  a  genetic  background.  A  high  prevalence
f  HLA-B8  and  DR3  has  been  observed  in  both  diseases,
hereas  the  presence  of  HLA-DR4  appears  to  predispose
o  AIH  and  protect  from  PSC.  The  HLA-DR52  allele  seems
o  be  associated  with  PSC:  In  relation  to  AIH/PSC  overlap
yndrome,  the  published  literature  indicates  that  DR3  fre-
uency  is  similar  to  that  of  patients  that  have  only  PSC  or
IH.13
The  evidence  suggests  that  the  diseases  frequently
evelop  sequentially.  This  was  illustrated  in  a  study  on
38  patients  with  AIH  in  which  16  (6%)  met  the  AIH/PSC  over-
ap  criteria.37 Said  study  reported  that  in  approximately  50%
f  the  patients  with  AIH/PSC,  the  initial  diagnosis  was  AIH
ith  a  later  development  of  PSC  cholangiographic  changes
nd  in  the  other  50%  the  2  diseases  presented  initially.37
n  another  study  on  16  patients  with  AIH/PSC,  62%  had  ini-
ially  been  diagnosed  with  AIH  and  later  developed  PSC
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aFigure  2  Severe  periductal  ‘‘onion  skin’’  ﬁbrosis,  character-
istic  of  PSC.
characteristics,  18%  of  patients  with  PSC  later  developed  AIH
characteristics,  and  18%  had  the  criteria  of  both  diseases
at  the  onset.  It  is  striking  that  in  this  last  study  the  cases
were  reviewed  retrospectively  and  they  found  biochemical
and  histologic  characteristics  of  both  diseases  in  100%  of  the
patients  at  the  onset,  regardless  of  the  initial  diagnosis;  this
suggests  that  the  biochemical  phenotype  is  initially  differ-
ent  in  the  diseases  as  single  entities.38 On  the  other  hand,
it  is  uncommon  that  patients  with  PSC  later  develop  AIH
characteristics.10,15
Diagnosis
AIH  scores  are  not  useful  for  deﬁning  its  cholestatic  pheno-
types  and  liver  biopsy  together  with  clinical  judgment  are
the  best  tools  at  present.34
In  relation  to  the  biochemical  parameters,  classic  AIH
tends  to  have  higher  transaminase  values  compared  with
AIH/PBC  and  AIH/PSC,  and  AIH/PSC  tends  to  have  higher
AP  values  than  classic  AIH  and  AIH/PBC,  although  there  is
important  overlap  of  said  values  and  therefore  these  param-
eters  do  not  appear  useful  for  their  differenctiation.37
In  histology,  interface  hepatitis,  portal  edema  or  ﬁbro-
sis,  ductopenia,  ductular  proliferation,  or  ﬁbro-obliterating
cholangitis  can  be  observed8 (ﬁg.  2).
The  antibody  proﬁle  is  variable.  In  a  study  on  16  patients
with  AIH/PSC  overlap,  81%  of  the  patients  were  found  to  be
positive  for  pANCA,  62.5%  for  antinuclear  antibodies,  and
50%  for  SMA.38
In  patients  meeting  the  AIH  diagnostic  criteria,  imaging
studies  that  show  regeneration  nodules  >  3  cm,  peripheral
atrophy  of  the  hepatic  parenchyma,  and  a  beaded  cholangio-
graphic  pattern  (ﬁg.  3)  have  a  speciﬁcity  of  100%  for  AIH/PSC
overlap  syndrome.39 Those  ﬁndings  appear  to  be  attributed
to  the  PSC  component  because  they  have  also  been  observed
in  PSC  as  a  single  entity.  It  is  worth  mentioning  that  the  pres-
ence  of  cirrhosis  can  alter  the  architecture  of  the  hepatic
ducts  and  consequently  the  imaging  patterns.39
Cholangiographic  changes  appear  to  be  expressed  as  late
changes.  This  was  shown  in  a  study  on  16  patients  with
AIH/PSC  in  which,  despite  having  histologic  PSC  and  bio-
chemical  cholestatic  changes,  none  of  the  patients  that
underwent  imaging  studies  had  cholangiographic  changes;
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hey  developed  during  follow-up  in  87%  of  the  patients.38 In
nother  prospective  5-year  study,  41  patients  with  PSC  were
ollowed,  7  of  whom  had  AIH/PSC  overlap  (17%).  In  all  the
atients,  initial  diagnosis  was  immunosuppressant-resistant
IH  for  which  endoscopic  cholangiography  was  carried  out.  It
evealed  cholangiographic  changes  at  a  median  of  17  months
fter  AIH  diagnosis.40
Inﬂammatory  bowel  disease  is  frequent  in  patients  with
IH/PSC  (approximately  25%).38 It  is  known  that  41%  of  the
atients  that  present  with  AIH  and  UC  have  cholangiographic
esions.  This  justiﬁes  the  performance  of  cholangiography  in
his  patient  subgroup,  unlike  the  patients  with  AIH  that  do
ot  have  inﬂammatory  bowel  disease,  whose  prevalence  of
holangiographic  lesions  is  10%.8
AIH/PSC  overlap  should  be  suspected  in  adults  diagnosed
ith  AIH  that  have  poor  therapeutic  response  to  steroids,
holestasis,  histologic  biliary  lesion,  absence  of  AMAs,  and
oexisting  inﬂammatory  bowel  disease.  It  is  thus  reasonable
o  order  an  NMR  cholangiography  if  any  of  those  character-
stics  are  identiﬁed.
reatment
here  is  no  uniform  treatment  and  it  should  be
ndividualized.32 There  are  also  non-controlled  clinical  trials
n  patients  with  AIH/PSC  overlap  and  the  medical  treatments
nalyzed  in  classic  PSC  have  not  had  good  results,  given  that
one  have  demonstrated  beneﬁt  in  crude  or  transplantation-
ree  survival.15
The  EASL  consensus10 and  the  AASLD  guidelines4 for  PSC
ecommend  that  patients  with  AIH/PSC  overlap  be  treated,
long  with  endoscopic  therapy  when  indicated,  with  the
ombination  of  azathioprine  and  prednisone,  at  doses  of  1-
 mg/kg  and  0.5  mg/kg,  respectively.  The  prednisone  dose
hould  be  gradually  reduced  until  reaching  10-15  mg/d.
DCA  13-15  mg/kg/d  is  also  recommended,  underlining  the
act  that  responses  are  inconsistent  and  evidence  is  not
olid.  In  a  clinical  trial  conducted  on  150  patients  with  PSC,
 therapeutic  arms  were  randomly  carried  out;  the  ﬁrst
eceived  UDCA  at  a  dose  of  28-30  mg/kg  and  the  second
eceived  placebo.  The  study  was  suspended  after  6  years  due
o  therapeutic  futility  and  the  outcomes  were  evaluated.
espite  having  higher  improvement  rates  in  AST  and  alkaline
hosphatase  levels,  the  patients  in  the  UDCA  group  showed
 greater  risk  for  cirrhosis,  varices,  liver  transplantation,  or
eath,  as  well  as  higher  severe  adverse  effect  rates  than  the
atients  in  the  placebo  group.  Thus,  despite  their  not  having
een  studied  in  relation  to  AIH/PSC  overlap,41 high  doses  of
DCA  (28-30  mg/kg)  are  not  recommended.8,10,15
Steroid  treatment  is  usually  ineffective  in  adult  patients
ith  AIH/PSC  of  the  large  and  small  ducts,  in  patients  with
nd  without  inﬂammatory  bowel  disease.  Compared  with
atients  that  present  with  classic  AIH,  those  with  AIH/PSC
verlap  have  a  lower  biochemical  and  histologic  remission
ate  (22  vs  64%),  a  higher  rate  of  deterioration  during  treat-
ent  (33  vs  10%),  and  a  higher  rate  of  death  or  need  for  liver
ransplantation  (33  vs  8%).  In  addition,  treatment  response
ppears  to  be  slow;  in  a  study  on  16  patients  with  AIH/PCS38,
LT  level  normalization  took  approximately  26  months.
The  only  subgroup  of  patients  with  AIH/PSC  with  accept-
ble  rates  of  response  to  steroids  (approximately  89%)  and
ow  rates  of  progression  to  cirrhosis  are  children.  In  fact,
156  O.  Aguilar-Nájera  et  al.
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nigure  3  a  and  b.  Cholangiographic  images  typical  of  PSC  with
ith ‘‘beaded  pattern’’.
heir  results  could  be  considered  similar  to  the  response  seen
n  pure  AIH.10,32
Finally,  a  little-used  and  little-studied  therapy  in  AIH
verlap  syndromes  is  mycophenolate  mofetil.42 In  a  Dutch
tudy  on  45  AIH  patients,  15  of  them  had  AIH/PSC  overlap
nd  11  had  AIH/PBC  overlap.  The  remission  rate  was  57%
n  patients  that  did  not  respond  to  azathioprine  and  63%  in
atients  with  azathioprine-intolerance.42
rognosis
n  general,  therapeutic  response  and  outcome  is  better  in
atients  with  AIH/PBC  than  with  AIH/PSC.32
In  a  study  on  238  patients  with  AIH  in  which  16  (6%)  had
IH/PSC  overlap,  survival  in  the  AIH/PSC  patients  was  sig-
iﬁcantly  lower  than  in  the  patients  with  AIH  or  AIH/PBC
verlap.37 On  the  other  hand,  the  patients  with  AIH/PSC
ppeared  to  have  a  better  prognosis  than  the  patients  pre-
enting  with  PSC  alone.10 The  latter  is  exempliﬁed  in  a  study
n  which  the  patients  with  AIH/PSC  treated  with  immuno-
uppression  apparently  had  better  survival  than  the  patients
ith  classic  PSC  treated  with  UDCA.10,37,43
The  clinical  behavior  of  AIH/PSC  appears  to  be  differ-
nt  from  that  of  AIH  or  PSC  as  separate  entities  because,
n  the  one  hand,  treatment  response  is  lower  and  ﬁbro-
is  development  is  higher  compared  with  classic  AIH,  and
n  the  other  hand,  inﬂammatory  bowel  disease  prevalence
nd  the  development  of  cholangiocarcinoma  appear  to  be
ower  than  in  PSC  alone.  In  a  prospective  study  on  7  patients
ith  AIH/PSC,  none  of  the  patients  developed  cholangiocar-
inoma  in  an  88-month  follow-up  period.15,38,40 In  said  study,
he  patients  with  classic  PSC  showed  greater  disease  pro-
ression,  a  higher  liver  transplantation  rate,  a  higher  rate
f  intrahepatic  and  extrahepatic  neoplastic  development,
nd  a  higher  mortality  rate  compared  with  the  patients  with
IH/PSC  overlap.40
Reduced  aminotransferase  levels  do  not  appear  to  ade-
uately  predict  outcome,  given  that  in  a  study  on  16  patients
ith  AIH/PSC,  despite  achieving  normalization  of  ALT  lev-
ls  in  87%  of  the  patients,  56%  had  cirrhosis  in  follow-up
iver  biopsies  and  at  the  end  of  the  study;  after  a 12-
ear  follow-up  period,  75%  of  the  patients  presented  with
irrhosis.15,32,38 On  the  other  hand,  in  relation  to  PSC,  AP
as  shown  to  have  a  prognostic  value,  given  that  normal
s
f
r
lrm  strictures  (long  arrow)  and  saccular  dilations  (short  arrows)
alues  or  their  reduction  to  <  40%  of  their  initial  value,  was
ssociated  with  better  survival.34
Early-stage  disease  and  the  absence  of  cholangiographic
lterations  in  the  large  ducts  alone,  compared  with  the  small
ucts  alone,  appear  to  be  favorable  outcome  factors.32
utoimmune  hepatitis  overlap/undetermined
holestasis
eﬁnition
IH  overlap/cholestatic  syndrome  is  also  known  as  autoim-
une  cholangitis  and  consists  of  histologic  lesion  or  loss  of
he  bile  ducts,  negative  AMAs,  and  normal  cholangiography.
his  syndrome  can  include  seronegative  PBC  and  small  duct
SC.8,15
pidemiology
he  approximated  frequency  of  an  undetermined
holestatic  phenotype  in  patients  with  AIH  ranges  from
-11%.8
iagnosis
he  diagnosis  of  AIH/undetermined  cholestasis  is  made  when
here  is  AIH  with  data  of  cholestasis  and  histologic  bile  duct
amage,  negative  AMAs,  and  normal  cholangiography.15
Histologic  changes  in  AIH/cholestatic  syndrome  can  be
ortal  ﬁbrosis,  portal  edema,  and  ductopenia  characteris-
ic  of  PCS,  or  lymphoplasmacytic  inﬁltrate  with  interface
epatitis  and  bile  duct  lesion  suggestive  of  PBC.8,15,44
In  patients  with  AIH/undetermined  cholestasis,  upon  car-
ying  out  ample  serologic  evaluations  that  utilize  enzymatic
mmunoassays  based  on  the  gp210  and  sp100  antigens  and
itochondrial  components,  positivity  for  said  antibodies  has
een  found  in  35%  of  the  patients  with  negative  AMAs,  which
ould  support  seronegative  PBC  diagnosis.34
reatment  and  prognosis
reatment  with  immunosuppressant  drugs  or  UDCA  usually  is
ot  effective  in  patients  with  AIH/undetermined  cholesta-
is  overlap,  with  a therapeutic  failure  of  88-100%  and  need
or  transplantation  in  33%  of  the  patients.15,17,44,45 This  poor
esponse  is  worse  in  classic  AIH  and  AIH/PSC  overlap  of  the
arge  ducts.
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Data  conﬁdentiality.  The  authors  declare  that  no  patient
data  appear  in  this  article.Overlap  syndromes  of  autoimmune  hepatitis:  diagnosis  and  
Differential diagnoses
Inﬁltration  by  IgG4  +  plasma  cells  (>  5  per  high  power  ﬁeld)
has  been  described  in  3-35%  of  the  patients  with  AIH  and  this
could  be  part  of  a  spectrum  that  includes  AIH,  autoimmune
pancreatitis,  and  sclerosing  cholangitis.  The  usual  pheno-
type  in  this  group  of  patients  is  IgG4-related  autoimmune
hepatitis  as  the  dominant  component  and  PSC  as  the  clini-
cal  subcomponent.32 IgG4-related  cholangitis  is  a  systemic
disease  causing  hepatitis  as  well  as  sclerosing  cholangitis
and  can  be  confused  with  an  overlap  syndrome.  It  is  char-
acterized  by  elevated  IgG4  and  positive  IgG4  plasma  cell
inﬁltration  into  the  bile  ducts  and  hepatic  parenchyma.  In
addition,  it  can  be  associated  with  autoimmune  pancreatitis
and  IgG4-related  systemic  disease  that  involves  the  sali-
vary  glands,  retroperitoneum,  gastrointestinal  tract,  lymph
nodes,  kidneys,  and  lungs.15
IgG4-related  cholangitis  should  be  suspected  in  male
patients,  older  adults  without  inﬂammatory  bowel  dis-
ease,  with  strictures  that  are  predominantly  in  the  distal
choledochus,  imaging  abnormalities  in  the  pancreas,  or
multiorgan  involvement  with  data  of  hepatitis/sclerosing
cholangitis.  Approximately  9-22%  of  the  patients  with  clas-
sic  PSC  have  modest  increases  in  IgG4  (>  140  mg/dL),  but  an
IgG4  value  >  2 ULN  is  highly  speciﬁc  for  IgG4-related  cholan-
gitis.  It  is  important  to  mention  that  not  all  patients  with
IgG4-related  cholangitis  have  elevated  serum  levels  of  that
biomarker,  and  so  it  should  also  be  looked  for  in  the  tissue
for  the  histopathologic  analysis.11,15,46--50.
Various  drugs  and  herbal  remedies  can  also  cause  bio-
chemical  and  histologic  ﬁndings  of  hepatitis/cholangitis,  as
well  as  the  presence  of  antibodies.10,15
The  drugs  associated  with  chronic  hepatitis  with  the
presence  of  antibodies  are  minocycline,  nitrofurantoin,
hydralazine,  methyldopa,  halothane,  diclofenac,  isoniazid,
and  inﬂiximab.  On  the  other  hand,  the  drugs  associated
with  mixed  data  of  cholestasis  and  hepatocellular  damage
are  various  antibiotics  (amoxicillin/clavulanate,  trimetho-
prim/sulfamethoxazole,  erythromycin,  ﬂuoroquinolones,
and  tetracyclines),  antifungals  (ketoconazole  and  itracona-
zole),  antivirals  (stavudine,  didanosine,  and  nevirapine),
NSAIDs  (piroxicam,  diclofenac),  immunomodulators  (aza-
thioprine),  psychotropics  (chlorpromazine,  risperidone,
imipramine,  amitriptyline),  and  others,  such  as  captopril,
glibenclamide,  phenytoin.15
Herbs  and  dietary  supplements  that  have  been  associated
with  hepatitis  alone  or  cholestatic  hepatitis  are  various  Chi-
nese  herbs  (Jin  Bu  Huan,  Dai-saiko-to),  black  cohosh,  green
tea,  euphorbia,  chaparral,  and  some  Herbalife  products.15
Despite  the  suspension  of  said  drugs,  some  patients
may  progress  to  the  infrequent  entity  of  chronic  intra-
hepatic  cholestasis  that  simulates  PBC,  also  known  as
evanescent  bile  duct  syndrome  that  is  characterized  by
chronic  bile  duct  lesion,  ductopenia,  and  progression  to
cirrhosis.15,51
Finally,  there  are  other  disorders  among  the  differential
diagnosis  of  biochemical  alterations  consistent  with  hep-
atitis  and/or  cholestasis,  such  as  the  cholestatic  varieties
of  viral  hepatitis,  steatohepatitis  (alcoholic  and  non-
alcoholic),  inﬁltrating  disorders,  paraneoplastic  syndromes,
any  cause  of  liver  cirrhosis,  idiopathic  ductopenia  in  the
adult,  and  any  cause  of  secondary  sclerosing  cholangitis.11
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iver transplantation and overlap syndromes
here  are  few  studies  documenting  the  outcome  of
atients  with  overlap  syndromes  that  have  undergone
ransplantation.8,15,52
Approximately  25%  of  liver  transplantations  are  per-
ormed  in  patients  with  autoimmune  liver  diseases  and  the
revalence  of  disease  recurrence  increases  over  time.  Five-
ear  recurrence  is  17-42%  for  AIH,  12-13%  for  PBC,  and
2-60%  for  PSC.52
In  a  study  with  231  patients  that  underwent  liver  trans-
lantation  due  to  autoimmune  liver  disease,  5%  had  overlap
yndrome  (58%  AIH/PBC  and  42%  AIH/PSC).52 In  these
atients,  having  overlap  syndrome  was  found  to  be  an
ndependent  risk  factor  for  recurrence  in  the  graft.  Approx-
mately  69%  of  the  patients  with  overlap  syndromes  had
ecurrence  in  the  graft,  compared  with  approximately  30%
ecurrence  in  patients  with  an  autoimmune  liver  disease
lone.  In  addition,  recurrence  time  was  shorter  (67  months
n  overlap  syndromes  vs  >  135  months  in  the  patients  with
 single  disease).  It  was  striking  that  in  70%  of  the  patients
ith  a  pre-transplantation  diagnosis  of  overlap  syndrome,
ecurrence  developed  as  a  single  disease  in  70%  and  as  over-
ap  in  only  30%.  It  is  not  known  whether  these  patients
ill  develop  overlap  characteristics  as  time  goes  by.  The
igher  relapse  rates  in  the  graft  in  patients  with  overlap
yndromes  do  not  appear  to  result  in  greater  graft  loss  or
ower  survival.52 Furthermore,  a  Japanese  study  reported
hat  survival  rates  for  AIH  and  PBC/AIH  were  excellent  and
here  was  no  evidence  of  recurrence  in  the  following  6-year
ollow-up  period.15,53
onclusions
verlap  syndromes  in  the  autoimmune  liver  diseases  are  few
nd  there  is  a  lack  of  standardized  deﬁnitions.  At  present  it  is
ot  known  if  they  are  separate  entities  or  if  they  form  part
f  the  classic  diseases.  However,  it  is  important  to  recog-
ize  them  because  their  clinical  course  is  more  aggressive
nd  they  have  a  lower  therapeutic  response.  Therapeutic
vidence  is  scarce  in  regard  to  overlap  syndromes  and  the
ecommended  treatments  are  based  on  retrospective  stud-
es  and  extrapolated  from  the  experience  in  patients  with
lassic  diseases.  Randomized  clinical  trials  are  lacking  and
t  is  hoped  that  better  quality  evidence  on  this  theme  will
e  produced  in  the  near  future.
thical responsibilities
rotection  of  persons  and  animals.  The  authors  declare
hat  no  experiments  were  performed  on  humans  or  animals
or  this  study.ight  to  privacy  and  informed  consent.  The  authors
eclare  that  no  patient  data  appear  in  this  article.
1F
N
a
C
T
A
T
G
c
M
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
358  
inancial disclosure
o  ﬁnancial  support  was  received  in  relation  to  this  study/
rticle.
onﬂict of interest
he  authors  declare  that  there  is  no  conﬂict  of  interest.
cknowledgements
he  authors  wish  to  thank  Francisco  Daniel  Brisen˜o García,
astroenterology  Resident  at  the  Instituto  Nacional  de  Cien-
ias  Médicas  y  Nutrición  Salvador  Zubirán,  SSA,  Mexico  City,
exico.
eferences
1. Dhiman P, Malhotra S. Overlap syndromes: An emerging diag-
nostic and therapeutic challenge. Saudi J Gastroenterol.
2014;20:342--9.
2. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and manage-
ment of autoimmune hepatitis. Hepatology. 2010;51:2193--213.
3. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrho-
sis. Hepatology. 2009;50:291--308.
4. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management
of primary sclerosing cholangitis. Hepatology. 2010;51:660--78.
5. Chazouillères O, Wendum D, Serfaty L, et al. Long term outcome
and response to therapy of primary biliary cirrhosis-autoimmune
hepatitis overlap syndrome. J Hepatol. 2006;44:400--6.
6. Donaldson PT. Genetics of liver disease: Immunogenetics and
disease pathogenesis. Gut. 2004;53:599--608.
7. Trivedi PJ, Hirschﬁeld GM. Review article: Overlap syn-
dromes and autoimmune liver disease. Aliment Pharmacol Ther.
2012;36:517--33.
8. Czaja AJ. Diagnosis and management of the overlap syndromes
of autoimmune hepatitis. Can J Gastroenterol. 2013;27:417--23.
9. Chan AW,  Quaglia A, Haugk B, et al. Atlas of liver pathology.
New York: Springer Science Business Media; 2014.
0. Boberg KM, Chapman RW, Hirschﬁeld GM, et al. Overlap
syndromes: The International Autoimmune Hepatitis Group
(IAIHG) position statement on a controversial issue. J Hepatol.
2011;54:374--85.
1. European Association for the Study of the Liver. EASL Clinical
Practice Guidelines: Management of cholestatic liver diseases.
J Hepatol. 2009;51:237--67.
2. Rust C, Beuers U. Overlap syndromes among autoimmune liver
diseases. World J Gastroenterol. 2008;14:3368--73.
3. Schramm C, Lohse AW.  Overlap syndromes of cholestatic liver
diseases and auto-immune hepatitis. Clin Rev Allergy Immunol.
2005;28:105--14.
4. Haldar D, Hirschﬁeld GM. Overlap syndrome: A real syndrome.
Clin Liver Dis. 2014;3:43--7.
5. Bunchorntavakul C, Reddy KR. Diagnosis and management of
overlap syndromes. Clin Liver Dis. 2015;19:81--97.
6. Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary
cirrhosis/autoimmune hepatitis overlap syndrome: Clinical fea-
tures and response to therapy. Hepatology. 1998;28:296--301.
7. Czaja AJ. Frequency and nature of the variant syndromes of
autoimmune liver disease. Hepatology. 1998;28:360--5.
8. O’Brien C, Joshi S, Feld JJ, et al. Long-term follow-up
of antimitochondrial antibody-positive autoimmune hepatitis.
Hepatology. 2008;48:550--6.
9. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behav-
ior, and prognostic implications of antimitochondrial antibodies
3O.  Aguilar-Nájera  et  al.
in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:
1047--53.
0. Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are
effective in diagnosis of primary biliary cirrhosis and autoim-
mune hepatitis overlap syndrome. Clin Gastroenterol Hepatol.
2010;8:530--4.
1. Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrho-
sis: Overlaps with other autoimmune disorders. Semin Liver Dis.
2014;34:352--60.
2. Muratori P, Granito A, Pappas G, et al. The serological proﬁle
of the autoimmune hepatitis/primary biliary cirrhosis overlap
syndrome. Am J Gastroenterol. 2009;104:1420--5.
3. Donaldson P, Doherty D, Underhill J, et al. The molecular
genetics of autoimmune liver disease. Hepatology. 1994;20:
225--39.
4. Coss-Adame E, Granados J, Uribe M, et al. Does HLA-DR7 differ-
entiate the overlap syndrome of autoimmune hepatitis/primary
biliary cirrhosis (AIH-PBC) from those with autoimmune hepati-
tis type 1. Ann Hepatol. 2011;10:28--32.
5. Zepeda-Gomez S, Montano-Loza AJ, Zapata-Colindres JC, et al.
HLA-DR allele frequencies in mexican mestizos with autoim-
mune liver diseases including overlap syndromes. Immunol
Invest. 2009;38:276--83.
6. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response
to ursodeoxycholic acid and long-term prognosis in primary bil-
iary cirrhosis. Hepatology. 2008;48:871--7.
7. Czaja AJ. Review article: The prevention and reversal of hepatic
ﬁbrosis in autoimmune hepatitis. Aliment Pharmacol Ther.
2014;39:385--406.
8. Yoshioka Y, Taniai M, Hashimoto E, et al. Clinical proﬁle of
primary biliary cirrhosis with features of autoimmune hep-
atitis: Importance of corticosteroid therapy. Hepatol Res.
2014;44:947--55.
9. Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of
autoimmune hepatitis and primary biliary cirrhosis: Long-term
outcomes. Am J Gastroenterol. 2007;102:1244--50.
0. Jung HE, Jang JY, Jeong SW, et al. Prognostic indicators in
primary biliary cirrhosis: Signiﬁcance of revised IAHG (Interna-
tional Autoimmune Hepatitis Group) score. Clin Mol Hepatol.
2012;18:375--82.
1. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary
cirrhosis with additional features of autoimmune hepatitis:
response to therapy with ursodeoxycholic acid. Hepatology.
2002;35:409--13.
2. Czaja A. The overlap syndromes of autoimmune hepatitis. Dig
Dis Sci. 2013;58:326--43.
3. Kingham JG, Abbasi A. Co-existence of primary biliary cirrho-
sis and primary sclerosisng colangitis: A rare overlap syndrome
put in perspective. Eur J Gastroenterol Hepatol. 2005;17:
1077--80.
4. Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. Clin
Gastroenterol Hepatol. 2014;12:1430--8.
5. Abdalian R, Dhar P, Jhaveri K, et al. Prevalence of scleros-
ing cholangitis in adults with autoimmune hepatitis: Evaluating
the role of routine magnetic resonance imaging. Hepatology.
2008;47:949--57.
6. Lewin M, Vilgrain V, Ozenne V, et al. Prevalence of sclerosing
cholangitis in adults with autoimmune hepatitis: A prospective
magnetic resonance imaging and histological study. Hepatology.
2009;50:528--37.
7. Al-Chalabi T, Portmann BC, Bernal W,  et al. Autoimmune hep-
titis overlap síndromes: an evaluation of treatment response,
long-term outcome and survival. Aliment Pharmacol Ther.
2008;28:209--20.
8. Lüth S, Lohse A, Kanzler S, et al. Characteristics and
long-term prognosis of the autoimmune hepatitis/primary scle-
rosing cholangitis overlap syndrome. J Clin Gastroenterol.
2009;43:75--80.
treat
4
4
4
4
5
5
5Overlap  syndromes  of  autoimmune  hepatitis:  diagnosis  and  
39. Hyslop WB, Kierans AS, Leonardou P, et al. Overlap syndrome of
autoimmune chronic liver diseases: MRI ﬁndings. J Magn Reson
Imaging. 2010;31:282--9.
40. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and out-
come of autoimmune hepatitis/primary sclerosing cholangitis
overlap syndrome. Am J Gastroenterol. 2005;100:1516--22.
41. Lindor K, Kowdley K, Luketic V, et al. High-dose ursodeoxy-
cholic acid for the treatment of primary sclerosing cholangitis.
Hepatology. 2009;50:808--14.
42. Baven-Pronk AM, van Hoek B, Coenraad MJ, et al. The role
of mycophenolate mofetil in the management of autoimmune
hepatitis and overlap syndromes. Aliment Pharmacol Ther.
2011;34:335--43.
43. Karlsen TH, Franke A, Melum E, et al. Genomewide association
analysis in primary sclerosing cholangitis. Gastroenterology.
2010;138:1102--11.
44. Czaja AJ, Carpenter HA, Santrach PJ, et al. Autoimmune
cholangitis within the spectrum of autoimmune liver disease.
Hepatology. 2000;31:1231--8.45. Olsson R, Glaumann H, Almer S, et al. High prevalence
of small duct primary sclerosing cholangitis among patients
with overlapping autoimmune hepatitis and primary sclerosing
cholangitis. Eur J Intern Med. 2009;20:190--6.
5ment  159
6. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-
associated cholangitis: clinical proﬁle and response to therapy.
Gastroenterology. 2008;134:706--15.
7. Mayo MJ. Cholestatic liver disease overlap syndromes. Clin Liver
Dis. 2013;17:243--53.
8. Silveira MG. IgG4-associated cholangitis. Clin Liver Dis.
2013;17:255--68.
9. Alswat K, Al-Harthy N, Mazrani W, et al. The spectrum
of sclerosing cholangitis and the relevance of IgG4 eleva-
tions in routine practice. Am J Gastroenterol. 2012;107:
56--63.
0. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4
concentration in patients with primary sclerosing cholangitis.
Am J Gastroenterol. 2006;101:2070--5.
1. Bhamidimarri KR, Schiff E. Drug-induced cholestasis. Clin Liver
Dis. 2013;17:519--31.
2. Bhanji RA, Mason AL, Girgis S, et al. Liver transplantation
for overlap síndromes of autoimmune liver diseases. Liver Int.
2013;33:210--9.3. Yamashiki N, Sugawara Y, Tamura S, et al. Living-donor liver
transplantation for autoimmune hepatitis and autoimmune
hepatitis-primary biliary cirrhosis overlap syndrome. Hepatol
Res. 2012;42:1016--23.
